{
  "source": "PA-Med-Nec-Ocaliva.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2091-12\nProgram Prior Authorization/Medical Necessity\nMedication Ocaliva® (obeticholic acid)\nP&T Approval Date 5/2016, 6/2016, 6/2017, 6/2018, 6/2019, 6/2020, 11/2021, 6/2022,\n6/2023, 6/2024, 12/2024\nEffective Date 3/1/2025\n1. Background:\nOcaliva (obeticholic acid), a farnesoid X receptor (FXR) agonist, is indicated for the treatment of\nprimary biliary cholangitis (PBC), without cirrhosis or with compensated cirrhosis without\nevidence of portal hypertension, in combination with ursodeoxycholic acid (UDCA) in adults\nwith an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.\nThis indication is approved under accelerated approval based on a reduction in alkaline\nphosphatase (ALP). An improvement in survival or disease-related symptoms has not been\nestablished. Continued approval for this indication may be contingent upon verification and\ndescription of clinical benefit in confirmatory trials.1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Ocaliva will be approved based on all of the following criteria:\na. Diagnosis of primary biliary cholangitis\n-AND-\nb. One of the following:\n(1) Patient does not have cirrhosis\n-OR-\n(2) Patient has compensated cirrhosis without evidence of portal hypertension\n-AND-\nc. One of the following^:\n(1) Both of the following:\n(a) Used in combination with ursodeoxycholic acid (e.g., Urso, ursodiol)\n(b) Patient has failed to achieve an alkaline phosphatase (ALP) level of less than\n1.67 times the upper limit of normal after at least 12 consecutive months of\ntreatment with ursodeoxycholic acid (e.g., Urso, ursodiol)\n© 2024 UnitedHealthcare Services Inc.\n1\n-OR-\n(2) History of contraindication or intolerance to ursodeoxycholic acid (e.g., Urso,\nursodiol)\n-AND-\nd. Patient is not receiving Ocaliva in combination with Iqirvo (elafibranor) or Livdelzi\n(seladelpar)\n-AND-\ne. Prescribed by one of the following:\n(1) Hepatologist\n(2) Gastroenterologi",
    "ursodiol)\n-AND-\nd. Patient is not receiving Ocaliva in combination with Iqirvo (elafibranor) or Livdelzi\n(seladelpar)\n-AND-\ne. Prescribed by one of the following:\n(1) Hepatologist\n(2) Gastroenterologist\nInitial authorization will be issued for 12 months\nB. Reauthorization\n1. Ocaliva will be approved based on all the following criteria:\na. Submission of medical records (e.g., laboratory values) documenting a reduction in\nALP level from pre-treatment baseline (i.e., prior to Ocaliva therapy)\n-AND-\nb. One of the following:\n(1) Patient does not have cirrhosis\n-OR-\n(2) Patient has compensated cirrhosis without evidence of portal hypertension\n-AND-\nc. Patient is not receiving Ocaliva in combination with Iqirvo (elafibranor) or Livdelzi\n(seladelpar)\n-AND-\nd. Prescribed by one of the following:\n(1) Hepatologist\n(2) Gastroenterologist\nReauthorization will be issued for 12 months\n© 2024 UnitedHealthcare Services Inc.\n2\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n^Tried/failed alternative(s) are supported by FDA labeling.\n3. Additional Clinical Rules:\n• Supply limits may be in place.\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Ocaliva [package insert]. Morristown, NJ: Intercept Pharmaceuticals, Inc.; May 2022.\nProgram Prior Authorization/Medical Necessity – Ocaliva (obeticholic acid)\nChange Control\nDate Change\n5/2016 New program.\n6/2016 Changed clinical criteria based on FDA approved label.\n7/2016 Added Indiana and West Virginia coverage information.\n11/2016 Administrative change. Added California coverage information.\n6/2017 Annual review. Added prescriber req",
    "sed on FDA approved label.\n7/2016 Added Indiana and West Virginia coverage information.\n11/2016 Administrative change. Added California coverage information.\n6/2017 Annual review. Added prescriber requirement to reauthorization\ncriteria. State mandate reference language updated.\n6/2018 Annual review. Updated references.\n6/2019 Annual review with no changes.\n6/2020 Annual review with no changes.\n11/2021 No changes to coverage criteria.\n6/2022 Changed clinical criteria based on changes to prescribing information.\nRevised order of listing of two criteria to better align with prescribing\ninformation. Added footnote that tried/failed alternative(s) are\nsupported by FDA labeling. Background and reference updated.\n6/2023 Annual review with no changes to coverage criteria. Updated reference.\n6/2024 Annual review. Updated initial authorization to 12 months.\n12/2024 Added not receiving in combination language to criteria.\n© 2024 UnitedHealthcare Services Inc.\n3"
  ]
}